Citadel Advisors
ABCL icon

Citadel Advisors’s AbCellera Biologics ABCL Stock Holding History

Citadel Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
1,586,512
+225,407
+17% +$1.1M ﹤0.01% 3238
2026
Q1 		$4.75M Sell
1,361,105
-473,403
-26% -$1.7M ﹤0.01% 4428
2025
Q4 		$6.27M Buy
1,834,508
+825,893
+82% +$3.69M ﹤0.01% 3939
2025
Q3 		$5.07M Sell
1,008,615
-1,881,145
-65% -$8.29M ﹤0.01% 4340
2025
Q2 		$9.91M Buy
2,889,760
+1,075,286
+59% +$2.68M ﹤0.01% 3033
2025
Q1 		$4.05M Buy
1,814,474
+1,217,223
+204% +$3.49M ﹤0.01% 4238
2024
Q4 		$1.75M Sell
597,251
-902,389
-60% -$2.51M ﹤0.01% 5911
2024
Q3 		$3.9M Buy
1,499,640
+26,430
+2% +$73.2K ﹤0.01% 4350
2024
Q2 		$4.36M Buy
1,473,210
+708,377
+93% +$2.68M ﹤0.01% 3963
2024
Q1 		$3.46M Buy
764,833
+186,527
+32% +$952K ﹤0.01% 4555
2023
Q4 		$3.3M Sell
578,306
-171,425
-23% -$794K ﹤0.01% 4490
2023
Q3 		$3.45M Sell
749,731
-1,444,039
-66% -$8.78M ﹤0.01% 4247
2023
Q2 		$14.2M Buy
2,193,770
+719,890
+49% +$4.91M ﹤0.01% 2248
2023
Q1 		$11.1M Buy
1,473,880
+8,884
+0.6% +$80.7K ﹤0.01% 2673
2022
Q4 		$14.8M Buy
1,464,996
+968,448
+195% +$11.2M ﹤0.01% 2310
2022
Q3 		$4.91M Buy
496,548
+329,348
+197% +$3.61M ﹤0.01% 3907
2022
Q2 		$1.78M Sell
167,200
-1,942
-1% -$16.4K ﹤0.01% 5787
2022
Q1 		$1.65M Sell
169,142
-248,948
-60% -$2.36M ﹤0.01% 6523
2021
Q4 		$5.98M Buy
418,090
+57,471
+16% +$872K ﹤0.01% 3989
2021
Q3 		$7.23M Sell
360,619
-42,990
-11% -$760K ﹤0.01% 3633
2021
Q2 		$8.88M Buy
403,609
+263,034
+187% +$7.25M ﹤0.01% 3276
2021
Q1 		$4.77M Sell
140,575
-291,782
-67% -$11.6M ﹤0.01% 4358
2020
Q4 		$17.4M Buy
+432,357
New +$19.8M ﹤0.01% 1953

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Citadel Advisors's ABCL Position: Q2 2026 in Review

Citadel Advisors increased its AbCellera Biologics (ABCL) stake by 17% in Q2 2026, buying an estimated $1.1M and bringing the position to 1,586,512 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

Citadel Advisors first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $17.4M in Q4 2020. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Citadel Advisors held 1,586,512 shares of AbCellera Biologics worth $12.5M as of Q2 2026.
  • Citadel Advisors bought 225,407 AbCellera Biologics shares in Q2 2026, an estimated $1.1M.
  • AbCellera Biologics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3238 holding.
  • Citadel Advisors first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • Citadel Advisors's AbCellera Biologics position peaked at $17.4M in Q4 2020.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.